Acousia Completes Patient Enrollment for Cisplatin Ototoxicity Prevention Study
The Phase 2 PROHEAR trial is evaluating ACOU085 (Bimokalner) for its efficacy in protecting hearing during chemotherapy.
The Phase 2 PROHEAR trial is evaluating ACOU085 (Bimokalner) for its efficacy in protecting hearing during chemotherapy.
Researchers achieved a breakthrough by keeping a sliver of the mammalian cochlea alive outside the body, directly revealing the biomechanics of hearing and opening new avenues to treat sensorineural hearing loss.
Sensorion’s Phase 1/2 Audiogene trial of the gene therapy SENS-501 for infants and toddlers with OTOF-related congenital deafness shows promising early safety and hearing improvement data, particularly in one patient, with a higher dose cohort now underway.
Cilcare raised €40 million in Series A funding to initiate two clinical trials in 2025 for treatment of cochlear synaptopathy.
In an article published on the ”Discover Magazine” website, author Sarah Katz challenges the view in the scientific community that deafness is a problem that needs to be cured, potentially by new CRISPR technology that could eliminate a TMC1 gene mutation.
In this case study, a man with hearing loss after a stroke benefits from hyperbaric oxygen therapy and steroid treatments.
Sound Pharmaceuticals' Phase 3 trial of an anti-inflammatory drug for Meniere’s disease showed significant improvements in hearing loss.